Biomarkers of extracellular matrix formation are associated with acute-on-chronic liver failure
Annarein J.C. Kerbert,Saurabh Gupta,Eman Alabsawy,Iwona Dobler,Ida Lønsmann,Andrew Hall,Signe Holm Nielsen,Mette J. Nielsen,Henning Gronbaek,Àlex Amoros,Dave Yeung,Jane Macnaughtan,Rajeshwar P. Mookerjee,Stewart Macdonald,Fausto Andreola,Richard Moreau,Vicente Arroyo,Paolo Angeli,Diana J. Leeming,William Treem,Morten A. Karsdal,Rajiv Jalan
DOI: https://doi.org/10.1016/j.jhepr.2021.100355
IF: 9.917
2021-12-01
JHEP Reports
Abstract:BACKGROUND & AIMS: <AbstractText Label="BACKGROUND & AIMS" NlmCategory="OBJECTIVE">Acute-on-chronic liver failure (ACLF) is characterised by organ failure(s), high short-term mortality, and, pathophysiologically, deranged inflammatory responses. The extracellular matrix (ECM) is critically involved in regulating the inflammatory response. This study aimed to determine alterations in biomarkers of ECM turnover in ACLF and their association with inflammation, organ failures, and mortality.</AbstractText>METHODS: <AbstractText Label="METHODS" NlmCategory="METHODS">We studied 283 patients with cirrhosis admitted for acute decompensation (AD) with or without ACLF, 64 patients with stable cirrhosis, and 30 healthy controls. A validation cohort (25 ACLF, 9 healthy controls) was included. Plasma PRO-C3, PRO-C4, PRO-C5, PRO-C6, and PRO-C8 (<i>i.e.</i> collagen type III-VI and VIII <i>formation</i>) and C4M and C6M (<i>i.e.</i> collagen type IV and VI <i>degradation</i>) were measured. Immunohistochemistry of PRO-C6 was performed on liver biopsies (AD [n = 7], ACLF [n = 5]). A competing-risk regression analysis was performed to explore the prognostic value of biomarkers of ECM turnover with 28- and 90-day mortality.</AbstractText>RESULTS: <AbstractText Label="RESULTS" NlmCategory="RESULTS">PRO-C3 and PRO-C6 were increased in ACLF compared to AD (<i>p</i> = 0.089 and <i>p</i> <0.001, respectively), whereas collagen degradation markers C4M and C6M were similar. Both PRO-C3 and PRO-C6 were strongly associated with liver function and inflammatory markers. Only PRO-C6 was associated with extrahepatic organ failures and 28- and 90-day mortality (hazard ratio [HR; on log-scale] 6.168, 95% CI 2.366-16.080, <i>p</i> <0.001, and 3.495, 95% CI 1.509-8.093, <i>p</i> = 0.003, respectively). These findings were consistent in the validation cohort. High PRO-C6 expression was observed in liver biopsies of patients with ACLF.</AbstractText>CONCLUSIONS: <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study shows, for the first time, evidence of severe net interstitial collagen deposition in ACLF and makes the novel observation of the association between PRO-C6 and (extrahepatic) organ failures and mortality. Further studies are needed to define the pathogenic significance of these observations.</AbstractText>LAY SUMMARY: <AbstractText Label="LAY SUMMARY" NlmCategory="BACKGROUND">This study describes a disrupted turnover of collagen type III and VI in Acute-on-chronic liver failure (ACLF). Plasma biomarkers of these collagens (PRO-C3 and PRO-C6) are associated with the severity of liver dysfunction and inflammation. PRO-C6, also known as the hormone endotrophin, has also been found to be associated with multi-organ failure and prognosis in acute decompensation and ACLF.</AbstractText>